Aimei Health Technology II ^{, Nasdaq: AHJKU}

We are a blank check company incorporated under the laws of the Cayman Islands. Although there is no restriction or limitation on what industry our target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation. We anticipate targeting what are traditionally known as “small cap” companies domiciled in North America, Europe and/or the Asia Pacific (“APAC”) regions that are developing assets in the biopharmaceutical, medical technology/medical device and diagnostics space which aligns with our officer’s and directors' experience in operating health care companies and in drug and device technology development as well as diagnostic and other services. We will be focused on companies in disruptive and other value added subsegments of healthcare that have the potential for significant gains in the next five years. Our ideal company will be institutionally backed, with a high-quality management team and a demonstrated ability to raise money from the private capital markets. Our plan is to focus on the esoteric/specialty diagnostic market that is quickly emerging as a critical component of the medical health system as the concept of therapeutics, diagnostics, medical devices and artificial intelligence merge into a single focus of optimizing patient care. Mr. Heung Ming Wong, our CEO, CFO, and Director, has over twenty years’ experience in finance, accounting, internal control, and corporate governance matters.